Prime Medicine, Inc.
PRME
$3.55
$0.3310.25%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -52.59M | -51.89M | -42.28M | -52.52M | -55.33M |
| Total Depreciation and Amortization | 1.86M | 1.70M | 1.72M | 1.56M | 1.54M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 8.77M | 8.99M | 7.94M | 7.97M | 13.05M |
| Change in Net Operating Assets | 548.00K | -7.65M | 48.86M | 17.08M | -4.75M |
| Cash from Operations | -41.41M | -48.86M | 16.25M | -25.91M | -45.49M |
| Capital Expenditure | -1.57M | -2.42M | -1.79M | -1.28M | -1.90M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 4.34M | -45.32M | 50.04M | 51.62M | 8.80M |
| Cash from Investing | 2.77M | -47.74M | 48.25M | 50.34M | 6.89M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 197.00K | -- | 1.00K | 38.51M | 35.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 6.00M | 0.00 | 0.00 | 0.00 |
| Cash from Financing | 197.00K | 6.00M | 1.00K | 38.51M | 35.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -38.44M | -90.60M | 64.50M | 62.94M | -38.56M |